Back to Alzheimers Disease
NCT00471211
NCT00471211
Who may be able to join
Who might be able to join this trial:
- You have been diagnosed with what doctors believe is early Alzheimer's disease
- You are already taking a specific type of Alzheimer's medication (called an acetylcholinesterase inhibitor) at a steady, unchanged dose
- You are living in the community (for example, at home), rather than in a care facility
- Your overall health condition is stable
Who may not be able to join:
- You have a serious or unstable health condition that is not well controlled
- You have a recurring major mental health disorder
- You are currently being treated with a medication called memantine
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Trial details
Status
Completed
Phase
Phase 2
Sponsor
Prana Biotechnology Limited
Registry
clinicaltrials_gov
Start date
1 December 2006
Est. completion
1 December 2007
Where this trial is recruiting
🇦🇺 Australia
🇸🇪 Sweden
7 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Safety
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.